

MusclePharm Corp
Form 10-Q/A
December 04, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Amendment No. 1

To

FORM 10-Q

**x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the quarterly period ended: **March 31, 2015**

OR

**.. TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the transition period from _____ to _____

Commission File Number: **000-53166**

MUSCLEPHARM CORPORATION

(Exact name of registrant as specified in its charter)

EXPLANATORY NOTE

The following is Amendment No. 1 to the Quarterly Report on Form 10-Q for the three months ended March 31, 2015 (the “Form 10-Q”) of MusclePharm Corporation. This Amendment No. 1 is being filed to solely to refile Exhibit 10.4, the Option Agreement by and between MusclePharm Corporation and F.H.G Corporation, effective March 2, 2015 (the “Agreement”) to the Form 10-Q to include certain portions of such exhibit which had been omitted from such exhibit when filed with the Form 10-Q pursuant to a request for confidential treatment filed with the SEC (the “CTR”).

This Form 10-Q/A should be read in conjunction with the Form 10-Q, which continues to speak as of the date of the Form 10-Q. Except as specifically noted above, this Form 10-Q/A does not modify or update disclosures in the original Form 10-Q. Accordingly, this Form 10-Q/A does not reflect events occurring after the filing of the Form 10-Q or modify or update any related or other disclosures.

PART II. OTHER INFORMATION

Item 6. Exhibits.

Exhibit No. Description

10.4*	Option Agreement by and between MusclePharm Corporation and F.H.G Corporation, effective March 2, 2015
31.1*	Rule 13 (A) – 14(A) Certification of Principal Executive Officer
31.2*	Rule 13 (A) – 14(A) Certification of Principal Financial Officer
32.1*	Section 1350 Certification of Principal Executive Officer
32.2*	Section 1350 Certification of Principal Financial Officer

*Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MUSCLEPHARM CORPORATION

Date: December 4, 2015 By: /s/ Brad J. Pyatt
Name: Brad J. Pyatt
Chief Executive Officer and President
Title:
(Principal Executive Officer)

Date: December 4, 2015 By: /s/ John Price
Name: John Price
Chief Financial Officer
Title: (Principal Financial Officer)
(Principal Accounting Officer)